Literature DB >> 3280726

p53 in chronic myelogenous leukemia. Study of mechanisms of differential expression.

M Lübbert1, C W Miller, L Crawford, H P Koeffler.   

Abstract

The p53 is a nuclear protein that is associated with normal cellular proliferation and can cooperate with Ha-ras in causing cellular transformation in vitro. Lineage association is known to exist between p53 expression and normal lymphopoiesis, but not myelopoiesis. We studied the expression of p53 using chronic myelogenous leukemia (CML) cell lines, somatic hybrids of these cells, and leukemic cells from CML patients. Lymphoid CML lines expressed both p53 mRNA and protein. We also analyzed p53 synthesis by two B-lymphoid lines from the same CML patient; cells of one line were derived from the neoplastic clone, cells of the other were derived from the normal clone. Both synthesized equal amounts of a phosphorylated p53 protein. None of the myeloid CML lines expressed detectable p53 protein and two of four expressed negligible p53 mRNA. Two other myeloid CML lines and myeloid cells from three of four patients expressed p53 mRNA. These findings suggest that expression of the gene is not regulated normally in CML. Several approaches were pursued to explore the differential expression of p53. Southern blot analyses showed no gross alterations in the p53 gene from cells of either the expressing or the nonexpressing lines. No difference in the pattern of demethylated CpG sites was noted in the region of the p53 gene in cells from K562 (myeloid p53 nonexpressor) and in BV173 (lymphoid p53 expressor). The sites of demethylation clustered in and around the p53 promoter in both cell lines. Somatic hybrids formed between a p53 mRNA nonexpressor myeloid line (K562) and the parental p53 expressor lymphoid lines (Daudi, PUT) produced p53 mRNA and protein, suggesting that p53 is a dominantly expressed protein and that lack of expression in myeloid cells is not mediated by a trans-acting negative regulatory protein. DNA transfection experiments performed using the indicator gene chloramphenicol acetyltransferase attached to promoter sequences of p53 showed that these constructs were equally activated in BV173 (p53 expressor) and K562 (p53 mRNA nonexpressor). The mechanism of p53 regulation in CML remains unclear.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280726      PMCID: PMC2188905          DOI: 10.1084/jem.167.3.873

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  41 in total

1.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

2.  Effect of protein synthesis inhibitors on growth factor activation of c-fos, c-myc, and actin gene transcription.

Authors:  M E Greenberg; A L Hermanowski; E B Ziff
Journal:  Mol Cell Biol       Date:  1986-04       Impact factor: 4.272

3.  Inducible binding of a factor to the c-fos enhancer.

Authors:  R Prywes; R G Roeder
Journal:  Cell       Date:  1986-12-05       Impact factor: 41.582

4.  Multiple protein-binding sites in the 5'-flanking region regulate c-fos expression.

Authors:  M Z Gilman; R N Wilson; R A Weinberg
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

5.  Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture.

Authors:  S J Collins; R C Gallo; R E Gallagher
Journal:  Nature       Date:  1977-11-24       Impact factor: 49.962

6.  Characterization of the human p53 gene.

Authors:  P Lamb; L Crawford
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

7.  A non-T, non-B human leukemia cell line (NALM-1): establishment of the cell line and presence of leukemia-associated antigens.

Authors:  J Minowada; T Tsubota; M F Greaves; T R Walters
Journal:  J Natl Cancer Inst       Date:  1977-07       Impact factor: 13.506

8.  Increased expression of p53 protein in human leukemia cells.

Authors:  H P Koeffler; C Miller; M A Nicolson; J Ranyard; R A Bosselman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

9.  Expression of p53 in human leukemia and lymphoma.

Authors:  M Prokocimer; M Shaklai; H B Bassat; D Wolf; N Goldfinger; V Rotter
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

10.  Expression of the p53 oncogene in acute myeloblastic leukemia.

Authors:  L J Smith; E A McCulloch; S Benchimol
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

View more
  18 in total

1.  p53 expression in lymphatic malignancies.

Authors:  Y Soini; P Pääkkö; M Alavaikko; K Vähäkangas
Journal:  J Clin Pathol       Date:  1992-11       Impact factor: 3.411

2.  Nucleostemin depletion induces post-g1 arrest apoptosis in chronic myelogenous leukemia k562 cells.

Authors:  Negin Seyed-Gogani; Marveh Rahmati; Nosratollah Zarghami; Iraj Asvadi-Kermani; Mohammad Ali Hoseinpour-Feyzi; Mohammad Amin Moosavi
Journal:  Adv Pharm Bull       Date:  2013-12-23

3.  p53 in chronic myelogenous leukemia in acute phase.

Authors:  E Feinstein; G Cimino; R P Gale; G Alimena; R Berthier; K Kishi; J Goldman; A Zaccaria; A Berrebi; E Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

4.  Salarin C, a member of the salarin superfamily of marine compounds, is a potent inducer of apoptosis.

Authors:  Nathalie Ben-Califa; Ashgan Bishara; Yoel Kashman; Drorit Neumann
Journal:  Invest New Drugs       Date:  2010-08-24       Impact factor: 3.850

5.  Inhibition of Erythroleukemia Cell Growth by Triplex-forming RNAs.

Authors:  Richard N Re; Zhuo Zhang; Julia L Cook
Journal:  Ochsner J       Date:  2007

6.  High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.

Authors:  A Lavigueur; V Maltby; D Mock; J Rossant; T Pawson; A Bernstein
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

7.  GAAP-1: a transcriptional activator of p53 and IRF-1 possesses pro-apoptotic activity.

Authors:  Christophe Lallemand; Marta Palmieri; Brigitte Blanchard; Jean-Francois Meritet; Michael G Tovey
Journal:  EMBO Rep       Date:  2002-01-29       Impact factor: 8.807

8.  Wild-type p53 can inhibit oncogene-mediated focus formation.

Authors:  D Eliyahu; D Michalovitz; S Eliyahu; O Pinhasi-Kimhi; M Oren
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 9.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

10.  Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells.

Authors:  P Johnson; D Gray; M Mowat; S Benchimol
Journal:  Mol Cell Biol       Date:  1991-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.